{"name":"Eledon Pharmaceuticals","slug":"eledon","ticker":"ELDN","exchange":"NASDAQ","domain":"eledonpharm.com","description":"Eledon Pharmaceuticals is a clinical-stage immunology biotech company focused on developing therapies for autoimmune diseases. The company's top drugs include Tucatinib and JNJ-64356471. Eledon Pharmaceuticals is a relatively small player in the immunology biotech space, with a limited market presence.","hq":"Irvine, CA","founded":0,"employees":"","ceo":"David-Alexandre C. Gros","sector":"Clinical-Stage Immunology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":66267000,"netIncome":-45617000,"cash":22808000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Eledon Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Eledon Pharmaceuticals Announces Collaboration with National Institutes of Health (NIH) to Develop Novel Therapies for Autoimmune Diseases","summary":"Eledon Pharmaceuticals announced a collaboration with the National Institutes of Health (NIH) to develop novel therapies for autoimmune diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-16","type":"trial","headline":"Eledon Pharmaceuticals Announces Positive Interim Results from Phase 1/2 Clinical Trial of JNJ-64356471","summary":"Eledon Pharmaceuticals announced positive interim results from a Phase 1/2 clinical trial of JNJ-64356471, a potential treatment for autoimmune diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB1b2V4REV3THZRQzA0aFRJdUZTQUV3elJmSHlySlBwd25MaTB1cnV5aEctdm5IMzFoQVFHWUZVclRLSlRVZkhrd3B2N1ZWRDhlWDFqeWZkMmpkZVY4dWF4dnZlamJhUjZlRjBqb2d3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN) - Stock Titan","headline":"If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN)","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOaVJtNVlzZjZjZHVuVHQ4NnBtVm93ZUQ3TkVWTVE0RTU3bVI0YmxqSGo4UEVtS2R1bnk4N01wMXJTWl9BaGRPSzJvYTJKYzZLM2F6a00yYUhCVGF1clFGWjQ2b29uUE94cllNM2Z6LVhvTC0yMmsxdVVzeXR5bDJzeGVKczd1Z3RBTmVxQzFMQjhOZVY0QWZoT2pNakRRV2VidWgtcFRjX3p4bGtrN29HbDJIZFhnVXM3eldYeGMxV2tZQ1pIVEE?oc=5","date":"2026-03-16","type":"pipeline","source":"Seeking Alpha","summary":"Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha","headline":"Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNWWN5b2dNZEhsQndXbWNkZ292aXlSR21aR09iTXpURmZPSE5iZm5oRElFd0ZtUDREb0FNUHYxeFVURjg1SGxaWTQtbl9fZnZFMEUxYkdaWHFwRU5QMnFlaXVrQUlfa1psMVFoVHZJZDJkVVNmTng5WUROVTNtMDUzd2FRWUJwazdFXy12QVZn?oc=5","date":"2026-03-10","type":"regulatory","source":"Seeking Alpha","summary":"Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha","headline":"Eledon Pharma wins FDA orphan status for lead asset (ELDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSF83Z2psY3oyQmJZeUFQSkl2TC1aODBjNWZERkNkVzI3Zlp3WHNETXJpZjEycW1TOTZzd18yREhfQjltRXZtLXdxTW1ya0FHOVB1VXZ2RXRnZVhLZHo5YUcyclpYdng0UjNWOUZDaUlCMktqREpiLVAyc3pCbUFDeFZ1MnF1cUo4TVNRQ2lBR0ZJbXFtMlhiZXJubENVamRvOE5WRDhOZll1NUQ3OVdfUS10YU1fWVBEWHdj?oc=5","date":"2026-01-08","type":"pipeline","source":"Stock Titan","summary":"Drug helped 6 people stop using insulin and enable pig-to-human kidneys - Stock Titan","headline":"Drug helped 6 people stop using insulin and enable pig-to-human kidneys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOdU1IdlRNM0JaRHdScDUtWEpxQlI5RW5ORUFyOXVyTVBfRm9QcWxKNmRSNnIyckRZZUtoWXVuM2ZrNDQ3Nkt1Y3F0Mkpvbmw3T2FXREJYb094RmtGbXNfSEEzS1RpdGp5bEJHdXJES1M5T043eDZsbkRmb3BDNFgwR3ZpVHB3WGZQN29GY1EwbFFWcTBCS1ZkME9RX2lxTEdSS0Zqb3BtQkdzV3FYYlNBWjQtc3FDZXFjQ0JKenlZZXBvclFydzFkSVRHYWQwVnR4cW4zOVRYeXhvRlh4R0xWLWFnYlZnaWdpRVQxNFltbw?oc=5","date":"2026-01-08","type":"pipeline","source":"GlobeNewswire","summary":"Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - GlobeNewswire","headline":"Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQanBKWWtjRWVsV2hsckR5TWdzNEQyYWFXMkNtVVZreUVmME9mM094LVktdmdrRmJaUE4waHRLZGo2N1hvZlZvZkJnWHhSaE1HTUFPeXN4cUtibFpiN3R0clZ2NG5wdVdENHlwM3RFUnFSUzVfdGxwbjBDbEdyMXpIa3ZEVUJuVlQyVnZJWlFRbXFYTTRNNDdpaVlHWjhhXzJtUU5rTDhKUzZTWVFqRHcwY2hjdGJQRTNKdXNpbU5MRVdrZjUwaWEzQWRoSHBZRjR4cTY4WWNoOGNHcUxJZWJZOEluMlRPOHVlNkJGbE9UMzZQTUxpUFlQTVFrdU13NUx6Z1E?oc=5","date":"2025-11-14","type":"earnings","source":"GlobeNewswire","summary":"Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewswire","headline":"Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOaUpFV2xRdFBzcnNudUw5VS0yaURUTjZZZHQxaUpzR2dncW9ZUmN1eUk0RFFBeWdrbEoxSUhqMDZaeXZheGRvdXg5OW5DdEF6eDk2Z1pvZ1VqcWFGS3hEa0FOYldyWHlGTURYeFk1enoxejJ3WVNleF9ZYmNVbmMtNElLT0ZxYXNVcUtUMjdBeEdhdDkybG5nRi02MDdfbklpUmt2XzNIQjhHS0RBeWl0V2R2LThoTk5Mekh4bm9xUXpnMW5TSm5KOXh0Skp5SWUtRWRvbmpkNkRXMldwOWduWV9xODVnODQweVUtS0o3Y2FfYl9IRGVPUVBmSGtrS2ZYQVBRRFFCOU9DYWJvVFE?oc=5","date":"2025-11-10","type":"trial","source":"FinancialContent","summary":"Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern - FinancialContent","headline":"Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOSmIyZEtZNjA3amNvSTB5NVdKeHJiU3RtSGFJSjRkV2wwTGp2cjlDYzlRc0lfQ3ZsY1JmcnRxMk13SUZXd2E4QzNtTTJPQTd5amZMUnRFaHhyNTZxSUE0bENBbFJzcDR0TlVPTXpBYWs0OTFISmVBM2ptaUxReDR4OUt2QjB0RE9WYS12ejJzdzVubzZfY3E5S09UZXdDVGhmWk1EZndGNUxnWlhxcnZOR01vRFdlbkFQZlFBTE12MmlQQW12LV9WMHBtc2R1d01QU0JR?oc=5","date":"2025-11-10","type":"deal","source":"Investing.com","summary":"Leerink Partners lowers Eledon Pharmaceuticals stock price target to $5 from $8 - Investing.com","headline":"Leerink Partners lowers Eledon Pharmaceuticals stock price target to $5 from $8","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMDZhY1A0dkFUV3BZVjlzNlVjTUNjYWEzVXZOUHd1Z3hDVkJfQ3B4MEJKekVsVDV5NjRPb3RYWGhjT091X0J0a1B5RHp1ZGNPQnB0NTc5MF9KVGNDUlNVVy1NQjQtemYtMUtSQXI2T0kzVXNCVGNPNUJlUXhleDlCczhEWTYzWjhBU3FYcXR4RmpyNFlRU3NqVg?oc=5","date":"2025-11-09","type":"trial","source":"Yahoo Finance","summary":"Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects - Yahoo Finance","headline":"Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Merck & Co."],"therapeuticFocus":["Autoimmune Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":0,"period":"2016-12-31"},{"value":0,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":66267000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-45617000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":22808000,"cashHistory":[],"totalAssets":169009000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}